Leigh Baldwin & Co’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Leigh Baldwin & Co’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$311K	Buy	+7,500	New	+$302K	0.16%	127

Other funds holding FTXH

First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.44B AUM 38.08% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $34.5B AUM 23.55% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.38B AUM 24% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.42B AUM 19.31% 1-Year Est. Return

Benjamin Edwards Inc Clayton, Missouri $11.1B AUM 12.46% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

Advisory Services Network Atlanta, Georgia $8.32B AUM 29.07% 1-Year Est. Return

Leigh Baldwin & Co's FTXH Position: Q3 2026 in Review

Leigh Baldwin & Co opened a new position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q3 2026: 7,500 shares worth $311K. The stake represents 0.16% of the portfolio and ranks #127 among its holdings.

57 funds tracked by Wall St. Rank hold FTXH as of Q3 2026.

Leigh Baldwin & Co held 7,500 shares of First Trust Nasdaq Pharmaceuticals ETF worth $311K as of Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF was a new Leigh Baldwin & Co position in Q3 2026.
First Trust Nasdaq Pharmaceuticals ETF made up 0.16% of Leigh Baldwin & Co's portfolio in Q3 2026, its #127 holding.
57 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q3 2026.

Based on Leigh Baldwin & Co's 13F filing for Q3 2026, filed 13 Nov 2026.